Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. Fluence, a psychedelic therapy educational platform, will provide design and training for the psychotherapeutic portion of Tryp’s upcoming clinical trials, while Clinlogix, a global novel pharmaceutical product contract research organization, will provide support services. “Tryp announced on May 25 that global pharmaceutical contract development and manufacturing organization Alcami Corporation will support development of proprietary oral formulations for TRP-8802, which is manufactured by Albany Molecular Research Inc. (‘AMRI’). Tryp expects to manufacture its initial batch of cGMP psilocybin API [Active Pharmaceutical Ingredient] in September 2021.”
To view the full article, visit https://ibn.fm/yqZwG
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.